Our experimental results coupled to the observed association between OCT expression and pro-inflammatory cytokines in the kidneys of patients diagnosed with chronic kidney disease; provide the rationale for implementing a long-term anti-inflammatory therapy alongside the standard renal replacement therapy. Here, PLXNA2 is linked to chronic kidney disease.